Welcome to our dedicated page for Balchem Corporation news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem Corporation stock.
Founded in 1967, Balchem Corporation (NASDAQ: BCPC) offers innovative solutions and high-quality products across various industries globally. The company operates through four principal segments: Human Nutrition & Health, Specialty Products, Animal Nutrition & Health, and Industrial Products.
In the Human Nutrition & Health segment, Balchem provides essential choline nutrients and mineral amino acid chelates, supporting diverse health and nutritional applications. Their Animal Nutrition & Health segment delivers nutritional products derived from advanced microencapsulation and chelation technologies, alongside critical nutrient choline chloride, aimed at enhancing animal health.
The Specialty Products segment involves the repackaging and distribution of performance gases and chemicals, such as ethylene oxide, propylene oxide, and ammonia, for various industrial uses. Additionally, Balchem's Industrial Products segment caters to a broad range of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries.
Balchem employs approximately 1,000 people globally who are committed to driving the company into market leadership positions. Recent company achievements include their first professional sports partnership for VitaCholine®, spanning regions like the United States and the United Kingdom.
Balchem's dedication to research is evident in collaborations and studies, such as those exploring improved visuomotor performance through choline supplementation. The company's financial health and strategic growth initiatives continue to position it favorably within its chosen markets.
For more information, visit the Balchem Corporation website and stay updated with their latest news and developments.
Balchem Corporation (NASDAQ: BCPC) CFO Martin Bengtsson will present at the CJS Securities 23rd Annual "New Ideas for the New Year" Investor Conference on January 11, 2023, starting at 11:00 AM EST. The presentation will be accessible on Balchem's website post-conference. Balchem specializes in developing and marketing ingredients that enhance health and well-being across various industries, with three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ: BCPC) announced a dividend of $0.71 per share on December 5, 2022, marking a 10.9% increase from the previous year. This dividend will be paid on January 20, 2023, to shareholders on record as of December 27, 2022. The announcement signifies the fourteenth consecutive annual dividend increase, highlighting the company's robust financial performance and the Board's confidence in its long-term strategies.
Balchem Corporation (NASDAQ: BCPC) reported a net earnings increase to $25.2 million for Q3 2022, compared to $25.0 million in Q3 2021. Adjusted net earnings rose to $32.4 million, up 8% year-over-year, with adjusted EBITDA at $53.8 million, reflecting an 11.2% increase.
Net sales reached $244.3 million, a 23.4% increase driven by growth in all segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The effective tax rate declined to 18.8%. Cash flows from operations were $41.6 million, with free cash flow at $26.8 million.
Balchem Corporation (NASDAQ: BCPC) will host a conference call on November 4, 2022, at 11:00 AM ET to discuss its third quarter results. The financial results will be released before market opening on the same day. Interested parties can join the call by dialing 1-877-407-8289 or 1-201-689-8341 locally. A replay will be available until November 18, 2022, using conference ID #13733850. Balchem focuses on developing specialty ingredients across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ:BCPC) has announced its acquisition of Cardinal Associates Inc., known as Bergstrom Nutrition, a leading producer of methylsulfonylmethane (MSM) based in Vancouver, Washington. This strategic purchase enhances Balchem's product portfolio, particularly in joint health, sports nutrition, and beauty sectors. Bergstrom's OptiMSM® is recognized for its quality, holding a U.S. GRAS designation. The integration aims to accelerate growth and expand marketplace opportunities in Balchem's Human Nutrition and Health segment, aligning with its focus on longevity and performance.
Balchem Corporation (NASDAQ: BCPC) reported a strong second quarter for 2022, with net earnings of $29.8 million, up 31% from $22.7 million in Q2 2021. Adjusted net earnings rose to $34.4 million, reflecting a 13.3% increase year-over-year. Record net sales reached $236.7 million, marking a 17.0% growth, driven by Human, Animal, and Specialty Nutrition segments. The company completed the acquisition of Kappa Bioscience, enhancing its portfolio in the nutrition sector. Operational cash flow was robust at $48.2 million.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on July 29, 2022, at 11:00 AM ET to discuss its second quarter results, which will be published before market opening on the same day. CEO Ted Harris and CFO Martin Bengtsson will lead the call. Participants can access the conference by calling toll-free 1-877-407-8289. A replay will be available from two hours post-conclusion until August 12, 2022, using conference ID #13731403. For more information, visit www.balchem.com.
Balchem Corporation (NASDAQ:BCPC) has successfully completed its acquisition of Kappa Bioscience AS, a leading manufacturer of specialty vitamin K2, enhancing its portfolio in the human nutrition sector. This acquisition, initially announced on June 14, 2022, aims to capitalize on the growing demand for vitamin K2, which is vital for bone health, heart health, and immunity. Kappa's K2VITAL® is recognized for its purity and stability, backed by strong intellectual property and clinical research.
Balchem Corporation (NASDAQ:BCPC) announced the acquisition of Kappa Bioscience AS for an enterprise value of NOK 3.175B (approximately USD 338M). Kappa specializes in vitamin K2, essential for bone and heart health. This acquisition enhances Balchem's portfolio in science-based nutrients, expected to be accretive to earnings per share in 2022. Kappa's projected 2022 revenue is approximately NOK 500M (USD 53M). The deal will strengthen Balchem's market presence in Europe and the U.S., while Kappa will benefit from Balchem's established distribution network.
FAQ
What is the current stock price of Balchem Corporation (BCPC)?
What is the market cap of Balchem Corporation (BCPC)?
What industries does Balchem Corporation serve?
What are the main segments of Balchem Corporation?
What products are offered in the Human Nutrition & Health segment?
How does the Animal Nutrition & Health segment contribute to Balchem's portfolio?
What performance gases and chemicals are included in Balchem's Specialty Products segment?
How many employees does Balchem Corporation have?
What recent achievements has Balchem Corporation made?
Where can I find more information about Balchem Corporation?
How does Balchem contribute to research?
What is Balchem's market position?
